Nebilet Plus (Hydrochlorothiazide, Nebivolol)

Nebivolol selectively antagonizes β1‑adrenergic receptors in the heart, which decreases heart rate and contractility, thereby reducing cardiac output. In addition, it stimulates endothelial nitric‑oxide synthase, leading to nitric‑oxide‑mediated vasodilation and further lowering peripheral vascular resistance. This dual action contributes to its antihypertensive effect.

The specific dose of Nebilet Plus is determined by the prescribing clinician based on the patient’s blood pressure, renal function, and response to therapy. The prescriber selects the appropriate strength and titrates as needed, following clinical guidelines for combination antihypertensive treatment.

Safety of nebivolol and hydrochlorothiazide in pregnancy or lactation has not been fully established. The medication should only be used if the potential benefit justifies the potential risk to the fetus or infant, and it is generally avoided unless no suitable alternatives are available. Consultation with a healthcare professional is essential.

To place an order, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with single‑agent therapies, Nebilet Plus offers the convenience of a fixed‑dose combination, potentially improving adherence. It merges a β1‑blocker that reduces heart rate with a thiazide diuretic that promotes natriuresis, providing complementary blood‑pressure control. Alternatives may include ACE inhibitors, ARBs, or calcium‑channel blockers, each with distinct mechanisms and side‑effect profiles.

Nebilet Plus tablets should be stored at room temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the medication out of reach of children and do not use if the packaging is damaged or the tablets appear discolored.

Nebilet Plus is taken orally, usually once daily, with or without food, as directed by the prescribing physician. The tablet should be swallowed whole with a glass of water and not crushed or chewed, unless otherwise instructed by a healthcare professional.

The most serious adverse events include severe hypotension, acute kidney injury, significant electrolyte disturbances such as hyperkalemia or hyponatremia, and marked bradycardia. Patients should be monitored for signs of these conditions, and therapy should be discontinued promptly if they occur.

Nebilet Plus is contraindicated in patients with known hypersensitivity to nebivolol, hydrochlorothiazide, or any component of the formulation. It should also be avoided in individuals with severe renal impairment, uncontrolled heart failure, or a history of serious electrolyte imbalance, unless a physician determines that benefits outweigh risks.